StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
July 2, 2024 3:04 PM
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $1,001.00 price target on Eli Lilly (NYSE: LLY).The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Morgan Stanley on Eli Lilly (LLY): 'we expect LLY shares to trade flat to slightly up'
July 2, 2024 2:41 PM
Eli Lilly Alzheimer's drug approved by US FDA
July 2, 2024 1:55 PM
Biogen (BIIB) trades lower after after Lilly's Alzheimer's drug is approved
July 2, 2024 1:55 PM
Eli Lilly & Co. (LLY) Announces FDA Approval of Kisunla to Treat Early Symptomatic Alzheimer's Disease
July 2, 2024 1:36 PM
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
July 2, 2024 1:35 PM
Midday movers: Tesla, Rivian rise; Novo Nordisk, Pure Storage fall
July 2, 2024 11:50 AM
Eli Lilly & Co. (LLY) call put ratio 1 call to 1.2 puts with focus on August 870 and 890 calls
July 2, 2024 10:47 AM
Novo Nordisk, Eli Lilly stock slides after Biden op-ed calls for lower Ozempic, Wegovy Prices
July 2, 2024 9:12 AM
Biden Says Novo Nordisk (NVO) Must Cut Ozempic, Wegovy Prices
July 2, 2024 8:00 AM
Form 4 ELI LILLY & Co For: Jun 28 Filed by: LILLY ENDOWMENT INC
July 1, 2024 4:00 PM
Radionetics Oncology Enters Into Strategic Agreement With Lilly (LLY)
July 1, 2024 10:05 AM
Form 144 ELI LILLY & Co Filed by: LILLY ENDOWMENT INC
June 28, 2024 2:25 PM
Eli Lilly & Co. (LLY) option implied volatility flat as share price near record high
June 28, 2024 10:26 AM
